Infectious Disease Control

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent

* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America * "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023...

2023-07-21 16:47 1797

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...

2023-07-06 07:25 2606

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...

2023-07-06 07:19 2505

BGI CEO Yin Ye Advocates for Global Technology Sharing

SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference inRiyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity. "We ...

2023-07-05 14:17 1618

New Survey Reveals Insights on Singapore Workers' Preparedness for Digital Transformation

Study sheds light on perceptions, behaviours and changes towards digitalisation in the aftermath of the COVID-19 pandemic SINGAPORE, July 3, 2023 /PRNewswire/ -- Reeracoen, a leading provider of human resource services inSingapore, has released its latest report titled "Employee Attitudes Toward...

2023-07-03 07:45 2048

Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective

TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty  LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...

2023-06-29 00:00 2518

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...

2023-06-26 07:30 2221

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment  New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...

2023-06-25 20:00 2756

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...

2023-06-18 03:30 3623

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

* Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign * Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immu...

2023-06-16 06:05 2514

Treating COVID with Metformin Reduces Long COVID Rates

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseasessupported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection. The trial also saw a 42% reduction in emergency room visi...

2023-06-09 21:00 4729

China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use

CHENGDU, China, June 9, 2023 /PRNewswire/ -- On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in ...

2023-06-09 11:59 2924

Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa

ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes inWest Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today announced a deepening partnership with IFC to help the comp...

2023-06-06 19:52 2145

CAMH study confirms ongoing brain inflammation associated with long COVID

Researchers using advanced brain imaging are first to find increase in protein marker of inflammation in illness affecting 200 million globally TORONTO, June 2, 2023 /PRNewswire/ -- A new CAMH study published in the journalJAMA Psychiatry found elevated levels of inflammation in the brain of pa...

2023-06-02 04:07 2563

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or...

2023-06-01 08:00 2406

Chula Researchers Discover "Highly Effective Antibodies against COVID-19," Leading to "COVITRAP Nasal Spray" to Curb Infection at the Start

BANGKOK, May 24, 2023 /PRNewswire/ -- A research team at the Center of Excellence in Systems Biology, Faculty of Medicine,Chulalongkorn University, has identified "highly effective antibodies against COVID-19" from the human body. These antibodies have been developed into an innovation called "C...

2023-05-24 10:00 2472

SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum

* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...

2023-05-23 20:00 1781

The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

CHENGDU, China, May 18, 2023 /PRNewswire/ -- On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center,Sichuan University against the most recent cir...

2023-05-18 21:23 3973

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2023-05-18 20:25 3731

Parliamentarians from 23 countries call on G7 leaders to invest in neglected tropical diseases

Uniting to Combat Neglected Tropical Diseases (unitingtocombatntds.org) releases letter signed by 36 Parliamentarians from 23 countries calling on G7 Leaders to invest in NTDs. LONDON, May 17, 2023 /PRNewswire/ -- To: Fumio Kishida, Prime Minister, Japan (Host) Joe Biden, President, United Stat...

2023-05-17 17:40 2514
123456 ... 78

Week's Top Stories